The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Novo Nordisk ended its agreement with Hims & Hers for the sale of Wegovy after disagreements over marketing tactics and ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

Key Takeaways Hims & Hers shares plunged nearly 35% Monday after Novo Nordisk said it is pulling Wegovy from the platform, ...